Publish in this journal
Journal Information
Vol. 72. Issue 2.
Pages 138-144 (February 2019)
Download PDF
More article options
Not available
Vol. 72. Issue 2.
Pages 138-144 (February 2019)
Original article
DOI: 10.1016/j.rec.2018.02.009
Full text access
Insights Into Hypertrophic Cardiomyopathy Evaluation Through Follow-up of a Founder Pathogenic Variant
Entendimiento de la miocardiopatía hipertrófica mediante el estudio de una variante patogénica fundadora
Rebeca Lorcaa,
Corresponding author

Corresponding author: Departamento de Cardiología, Hospital Universitario Central de Asturias, Avda. Roma s/n, 33011 Oviedo, Asturias, Spain.
, Juan Gómeza, María Martína,b, Rubén Cabanillasc, Juan Calvod, Víctor Leóna, Isaac Pascuala, César Morísa,e,f, Eliecer Cotoa,e,f, José Julián R. Regueroa,e
a Unidad de Cardiopatías Familiares, Departamento de Cardiología y Genética Molecular, Hospital Universitario Central de Asturias (HUCA), Oviedo, Asturias, Spain
b Departamento de Biología Funcional, Universidad de Oviedo, Oviedo, Asturias, Spain
c Instituto de Medicina Oncológica y Molecular de Asturias (IMOMA), Oviedo, Asturias, Spain
d Departamento de Radiología, Hospital Universitario Central de Asturias (HUCA), Oviedo, Asturias, Spain
e Instituto de Investigación Sanitaria del Principado de Asturias (IISPA), Oviedo, Asturias, Spain
f Departamento de Medicina, Universidad de Oviedo, Oviedo, Asturias, Spain
This item has received
(Daily data update)
Article information
Full Text
Download PDF
Figures (2)
Tables (2)
Table 1. Characteristics of the 34 Affected Hypertrophic Cardiomyopathy Carriers of MYBPC3 p.G263X
Table 2. Comparison Between Founder Pathogenic Variants
Show moreShow less
Introduction and objectives

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. The current challenge relies on the accurate classification of the pathogenicity of the variants. Transthoracic echocardiography (TTE) is recommended at initial evaluation and cardiac magnetic resonance (CMR) imaging should also be considered. We aimed to reappraise the penetrance and clinical expression of the MYBPC3 p.G263* variant.


Three hundred and eighty-four HCM probands and a control cohort of 450 individuals were studied for the main sarcomere genes by next-generation sequencing. All MYBPC3 p.G263* carriers were identified and family screening was performed. Clinical information was recorded retrospectively before 2015 and prospectively thereafter. Extra effort was invested in performing CMR in all carriers, despite TTE results.


Thirteen HCM probands and none of the controls were carriers of the MYBPC3 p.G263* pathogenic variant (according to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology). A total of 39 carriers were identified with family screening. Most patients with HCM were asymptomatic at the time of diagnosis and showed late-onset disease. Despite having a relatively benign course in the young, late HCM-related complications could occur. Penetrance was around 70% when evaluated by TTE and was 87.2% with TTE plus CMR. Penetrance was age-dependent, reaching 100% in carriers older than 55 years.


MYBPC3 p.G263* shares with most truncating pathogenic variants in this gene a late onset, relatively benign clinical course in the young, and high penetrance. Cardiac magnetic resonance could be a useful tool to evaluate carriers despite TTE results.

Hypertrophic cardiomyopathy
Pathogenic variant
Truncated protein
Introducción y objetivos

La miocardiopatía hipertrófica (MCH) es la enfermedad cardiaca hereditaria más frecuente. El desafío actual radica en la clasificación precisa de la patogenicidad de variantes asociadas a las MCH. Para la evaluación inicial de la MCH se recomienda una ecocardiografía transtorácica (ETT). La cardiorresonancia magnética (CRM) también debe considerarse. El objetivo fue revaluar la penetrancia y expresión clínica de la variante patogénica MYBPC3 p.G263*.


Se estudiaron los principales genes sarcoméricos, mediante next-generation sequencing, en 384 índices con MCH y una cohorte control de 450 individuos sanos. Se identificaron todos portadores de MYBPC3 p.G263* y se realizó cribado familiar. Se recogió información clínica de manera retrospectiva hasta 2015 y prospectiva a partir de entonces. Se realizó un esfuerzo extra para realizar CRM en todos los portadores de la variante independientemente del resultado de la ETT.


Trece casos índice con MCH y ninguno de la cohorte control eran portadores de la variante MYBPC3 p.G263*, patogénica según el American College of Medical Genetics and Genomics y la Association for Molecular Pathology. Mediante cribado familiar se identificó a un total de 39 portadores. La mayoría se diagnosticó de MCH asintomática, con inicio tardío de la enfermedad y un curso relativamente benigno, pero con potenciales complicaciones tardías. Se encontró una penetrancia cercana al 70% evaluada por la ETT y del 87% por CRM. La penetrancia era edad-dependiente, y alcanzó el 100% en mayores de 55 años.


MYBPC3 p.G263* comparte con la mayoría de las variantes patogénicas truncantes en este gen un inicio tardío, un curso relativamente benigno en los jóvenes y una alta penetrancia. La CRM podría ser una herramienta útil en la evaluación de portadores independientemente de la ETT.

Palabras clave:
Miocardiopatía hipertrófica
Variante patogénica
Proteína truncada
Full Text

Hypertrophic cardiomyopathy (HCM) has been defined as the presence of increased left ventricular wall thickness that is not solely explained by abnormal loading conditions.1 Hypertrophic cardiomyopathy is the most common inherited cardiac disease, affecting 1 in every 500 people, with a well-described pathological, clinical, and genetic profile.2 Transthoracic echocardiography (TTE) is recommended in all patients with HCM at initial evaluation (class I, level B), and cardiac magnetic resonance (CMR) imaging should be considered at baseline assessment if local resources and expertise permit.1

In most cases, HCM is inherited as an autosomal dominant genetic trait,3 with incomplete penetrance and variable clinical expression.1 Sequencing of sarcomere protein genes identifies a disease-causing variant in up to 60% of cases,3 with MYH7 (cardiac beta-myosin heavy chain) and MYBPC3 (cardiac myosin-binding protein C) accounting for most of the variants.4 Although genetic testing is recommended for all HCM patients, to enable genetic screening of their relatives (class I, level B), the lack of robust data on specific genotype-phenotype associations has reduced its impact on clinical management beyond screening.1 Due to the small number of families with specific pathogenic variants properly reported in the literature, conclusions about genotype-phenotype correlations are limited.5 Nevertheless, this situation should improve, as better data are being collected.1 Nowadays, the real challenge relies in the accurate classification of the pathogenicity of variants,2,6 where an extra effort should be invested. A deep knowledge of variants’ mechanism of pathogenicity in each gene is imperative to achieve a reliable classification. Apparently, most pathogenic variants in sarcomeric genes are missense and behave according to a dominant negative mechanism.5,7 However, in MYBPC3, most pathogenic variants seem to have a different mechanism of pathogenicity.8

Description of founder pathogenic variants provides a unique opportunity to assess clinical relationships between a specific genotype and a phenotype. We previously reported the novel MYBPC3 p.G263* variant, which was the most frequently reported variant in a region of northern Spain.9 The aim of this study was to reappraise the penetrance and clinical expression of this likely founder pathogenic variant.

METHODSStudy Population and Genetic Analysis

Three hundred and eighty-four index HCM patients from our referral unit for familial cardiomyopathies were studied for the main sarcomere genes by next-generation sequencing as reported by Gómez et al.10,11 In addition, we sequenced with the same gene panel 450 individuals of the RENASTUR healthy cohort, aged 60 to 85 years and without symptoms of HCM, as reported elsewhere.10–13 Genomic DNA of patients was isolated from blood samples. Written informed consent was obtained from each participant and the research protocol followed our institutional ethics guidelines.

Variant Classification Analysis

The American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) recommends evaluating the pathogenicity of variants for Mendelian disorders with a probabilistic classification (“pathogenic”, “likely pathogenic”, “uncertain significance=VUS”, “likely benign”, and “benign”) based on multiple lines of evidence.6 Allele frequency > 5% in the Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium (ExAC) is used as stand-alone support for a benign interpretation. Thus, lower frequency variants reported since the 2015 ACMG/AMP guidelines, such as MYBPC3 p.G263*, were evaluated according to these documents.6

Clinical Evaluation

MYBPC3 p.G263* carriers were identified and managed following HCM guidelines.1 A pedigree was drawn for each proband and all available relatives underwent genetic screening.

Clinical evaluation including family and personal history, physical examination, resting 12-lead electrocardiography, 24-hour Holter monitoring, TTE, and CMR if possible were performed. Clinical information was recorded retrospectively before 2015 and prospectively from 2015 to date.

Two patients died without CMR. An extra effort was required to perform CMR in all living MYBPC3 p.G263* carriers, regardless of previous TTE results. This was performed in everyone except in persons with claustrophobia, implantable cardioverter-defibrillator, pregnancy or with advanced age. A clinical diagnosis of HCM was made in the presence of increased left ventricular wall thickness (≥ 15mm or ≥ 13 in HCM first-degree relatives), measured by any imaging technique, that was not solely explained by abnormal loading conditions.1 The HCM sudden death risk calculator14 was used.

Statistical Analysis

We used the SPSS v.19 statistical software package. Data are expressed as the mean ± standard deviation for continuous variables and as frequencies or percentages for categorical variables. The chi-square test or Fisher exact test was used to compare frequencies, whereas differences in continuous variables were evaluated with either the Student t test or Mann-Whitney U test. A P value < .05 was considered significant.

RESULTSNext-generation Sequencing

A pathogenic/likely pathogenic variant was identified in 34% of the HCM index cases (132/384), MYBPC3 being the most frequently affected gene (79/384 [21%]).

MYPBC3 p.G263* was identified in 13 apparently unrelated index cases (Figure 1) from the HCM cohort (13/384). The MYPBC3 p.G263* variant accounts for 10% of all pathogenic/likely pathogenic variants (13/132) found in this cohort and for 16.5% of those in the MYBPC3 gene (13/79). No other pathogenic/likely pathogenic variants were identified in these 13 patients (in our previous article, we reported the likely benign variant MYBPC3 R326Q, and the VUS MYH7 A100T).9

Figure 1.

Pedigree of families with hypertrophic cardiomyopathy, carrying MYBPC3 p.G263*. Fam., family; SD, sudden death. Symbols denote sex and disease status: +, carriers; –, noncarriers; ?, unknown phenotype; box, male; circle, female; darkened, phenotype of hypertrophic cardiomyopathy; slashed, deceased; clear symbol, unaffected; without sign, not studied.


None of the 450 controls were carriers of MYBPC3 p.G263*.

Variant Classification

According to ACMG/AMP,6MYBPC3 p.G263* is a pathogenic variant. It is a truncating variant in a gene in which loss of function is a known mechanism of disease, and computational evidence supports a deleterious effect on the gene. In addition, it is absent from controls in the Exome Sequencing Project, 1000 Genomes Project, and ExAC databases and in our RENASTUR control cohort. Furthermore, the robust segregation information in multiple affected family members (Figure 1) strongly supports its pathogenicity.

Study Population

MYPBC3 p.G263* was identified in 13 index cases (mean age, 56 years ± 14.7 standard deviation, 6 men). A total of 66 individuals from these 13 families were evaluated (Figure 1). Family genetic testing identified 39 carriers (17 men) and 27 noncarriers.

Thirty-four carriers (87.2%, 50% men) satisfied HCM criteria (Table 1). Disease penetrance, evaluated with TTE and CMR, was age-dependent, reaching 96.7% penetrance in carriers older than 40 years and 100% in those older than 55 years.

Table 1.

Characteristics of the 34 Affected Hypertrophic Cardiomyopathy Carriers of MYBPC3 p.G263X

  Men  Women  P  Total 
No.  17  50.00  17  50.00  34  100.00 
Age, y  50.7 ± 14.3    64 ± 15.5    < .05  56.75   
Reason for diagnosis
Asymtomatic  12  70.59  41.18  .09  19  55.88 
Incidental  17.65  5.88  .29  11.76 
Family screening  41.18  35.29  .73  13  38.24 
Abnormal electrocardiography  11.76  0.00  .15  5.88 
Symptoms  29.41  10  58.82  .09  15  44.12 
Atrial fibrillation  29.41  17.65  .43  23.53 
Stroke  5.88  11.76  .55  8.82 
Maximal LVWT, mm  19.8 ± 4.9    20.2 ± 5.1    .7  20.1  55.88 
Severe LVHa  11.76  5.88  .55  8.82 
LVNC  5.88  5.88  5.88 
Obstructionb  5.88  29.41  .08  17.65 
Severe obstructionc  5.88  17.65  .29  11.76 
Left atrium, mm  39.3 ± 7.8    39 ± 6.5    .9  39.15  114.71 
Systolic impairment  5.88  11.76  .55  8.82 
Mitral regurgitation III-IV  5.88  0.00  .32  2.94 
NYHA II  17.65  29.41    23.53 
NYHA III-IV  0.00  17.65    8.82 
Syncope  17.65  17.65  17.65 
Palpitations  5.88  11.76  .55  8.82 
Chest pain  5.88  23.53  .13  14.71 
NSVT  35.29  23.53  .42  10  29.41 
ABPR  11.76  0.00  .15  5.88 
FHSCD  0.00  5.88  .32  2.94 
CMR fibrosis  35.29  17.65  .24  26.47 
SCD risk
> 4%  23.53  23.53  23.53 
> 6%  11.76  17.65  .63  14.71 
Events (follow-up)
SCD  0.00  0.00  0.00 
ICD discharge  0.00  0.00  0.00 
Transplant  0.00  0.00  0.00 
Miomectomy/septal ablation  0.00  5.88  .32  2.94 

ABPR, abnormal blood pressure response during upright exercise; CMR, cardiac magnetic resonance; FHSCD, family history of sudden cardiac death; ICD, implantable cardioverter-defibrillator; LVH, left ventricular hypertrophy; LVNC, left ventricular noncompaction; LVWT, left ventricular wall thickness; NSVT, nonsustained ventricular tachycardia on Holter monitoring; NYHA, New York Heart Association; SCD, sudden cardiac death.

Unless otherwise indicated, data are expressed as No. (%) or mean ± standard deviation.


Maximal LVWT > 30 mm.


Left ventricular outflow tract gradient > 30 mmHg.


Left ventricular outflow tract gradient > 90 mmHg.

Of the 39 MYBPC3 p.G263* carriers, 24 underwent CMR, regardless of previous TTE results. Fibrosis was present in 37.5% of them. The CMR of 2 carriers with HCM exhibited features consistent with left ventricular noncompaction (LVNC). Cardiac magnetic resonance identified crypts unnoticed by TTE in 2 carriers without HCM.

Cardiac magnetic resonance was the key to properly diagnosing 8 patients (Figure 2). Without CMR, left ventricular hypertrophy in 6 carriers would have gone unnoticed by TTE. Moreover, CMR helped assess a borderline hypertrophy identified in TTE and in a differential diagnosis between HCM and hypertensive cardiomyopathy. The average time between TTE and CMR was 1.2 years ± 1.25. Had CMR not been performed, penetrance rates evaluated with TTE only would have decreased to 66.7% to 71.8%. Cardiac magnetic resonance did not identify any false positive of TTE.

Figure 2.

Example of a hypertrophic cardiomyopathy undetected on echocardiography (A) and visualized on cardiac magnetic resonance (B).


Men with the HCM phenotype were significantly younger than women. Interestingly, all clinically unaffected carriers were women younger than 55 years. These findings represent an overall 100% penetrance in men and 77.3% in women. Although there were other slight differences between sexes in clinical characteristics (Table 1), they did not reach statistical significance. The mean age at diagnosis was 50 ± 14 years in men and 59 years ± 15.5 in women. The mean age at genetic testing was 45 ± 15 years in male carriers, 54 ± 19 in female carriers, and 61 ± 15 in female carriers with HCM

Most patients (55.9%) were asymptomatic at diagnosis, especially in the context of family screening (Table 1). Although electrocardiography findings were not the main reason for cardiology referral, 85% of these findings in carriers were abnormal.

Only 1 patient had a family history of sudden cardiac death (SCD), when considered in first-degree relatives younger than 40 years (or any age if HCM was diagnosed). Nonetheless, SCD could appear at advanced ages and also in second-degree relatives (Figure 1).

The average SCD risk was low. However, in 9 patients the risk was higher (4 intermediate and 5 high). One patient with high risk died due to heart failure before implantable cardioverter-defibrillator implantation. An implantable cardioverter-defibrillator was implanted in the other 3 high-risk patients and implantation is pending in the fifth. Three of the 4 patients with intermediate risk also received an implantable cardioverter-defibrillator and implantation is being considered in the fourth. There were no cases of SCD or implantable cardioverter-defibrillator shocks. One patient's risk has diminished below 4% due to aging.

Only 3 patients developed left ventricular systolic impairment (being moderate/severe in the 2 with LVNC) and 3 had strokes (one with atrial fibrillation as a risk factor, another with LVCN and the third with both atrial fibrillation and LVNC).

DISCUSSIONAccurate Classification of Variants

The growing public awareness of heritable diseases and the new available sequencing techniques have dramatically increased clinical demand for genetic testing, as well as the number of variants requiring bioinformatic and clinical interpretation.2 Nowadays, the number of HCM pathogenic variants reported is higher than expected. Walsh et al.15 analyzed data from 7855 individuals testing for inherited cardiomyopathies, along with 60706 ExAC reference samples. It was found that 11.7% of individuals in ExAC have reported HCM variants, an enormous excess of disease prevalence, incompatible with the actual prevalence of HCM (0.5%). This proved that many reported variants have been misclassified. For this reason, an extra effort should be invested in adequate classification of the pathogenicity of variants. Deep knowledge of the mechanisms of pathogenicity of each gene is essential and ACMG/AMP criteria6 should be analyzed with caution.

Cardiomyopathy-causing variants in most myofilament proteins incorporate into the sarcomere, acting as dominant negatives, such as missense variants in MYH7.5,7 In contrast, most pathogenic variants in MYBPC3 are truncating, causing HCM through haploinsufficiency.8,16,17 Walsh et al.15 confirmed the association between HCM and both the missense variation in MYH7 and the truncating variant in MYBPC3.16 They analyzed predicted truncating and nontruncating variants in cardiomyopathies and calculated their etiological fraction, which estimates the proportion of cases in which having a rare variant in a gene was disease-causing. In genes whose truncating alleles are disease-causing, the odds ratio, comparing rare-variant carriers with noncarriers, is typically higher. MYBPC3 nontruncanting variants had an odds ratio of 5.7 (0.8 etiological fraction) whereas truncating variants had an odds ratio that was nearly 21 times higher (0.99 etiological fraction). In contrast, MYH7 truncating variants had an odds ratio of only 1.7 (0.4 etiological fraction) and nontruncanting variants had an odds ratio of 12 (0.92 etiological fraction).15

Information about adequately characterized pathogenic variants should be reported to improve global databases and help their interpretation in other areas of the world where these variants may not be present.

Clinical Phenotype and Comparison With Other Pathogenic Variants in MYBPC3

Although MYBPC3 pathogenic variants have been associated with a delayed onset of HCM (age > 40 years),18 mild hypertrophy, a low incidence of SCD, a relatively benign clinical course, and variability in the onset and prognosis of the disease has also been reported.19,20 Nevertheless, no differences in clinical phenotype have been attributable to a specific type of MYBPC3 variant.21 The high prevalence of founder pathogenic variants provides an opportunity to define their clinical profiles. Many founder pathogenic variants in MYBPC3 have been identified in some populations; interestingly, all of them were truncating variants17 and represented a large percentage (10%-25% to 58%) of the detected pathogenic variants in their countries of origin.22–29 The late onset of life-threatening HCM complications, delayed beyond reproductive age, has allowed its transmission to the next generations.24,25

Cardiac magnetic resonance enables 3-dimensional tomographic assessment of cardiac anatomy and has become an outstanding tool to evaluate cardiomyopathies. In fact, it is considered the noninvasive gold standard for the assessment of ventricular mass, volumes, and ejection fraction. Cardiac magnetic resonance is superior to TTE in the detection of left ventricular apical and anterolateral hypertrophy, aneurysms30 and thrombi.31 In some series, CMR has identified myocardial crypts in up to 70% of carriers of pathogenic variants without HCM.32–34 Although CMR is recommended in patients with inadequate echocardiographic windows (IB), sometimes its role in the HCM screening phase is limited, due to lack of availability of local resources.1 Thus, the penetrance of pathogenic variants in HCM is often evaluated based on TTE studies.

Unfortunately, in many studies of founder pathogenic variants, such as that by Adalsteinsdottir et al.,22 only probands or patients with known HCM phenotype were included, so disease penetrance could not be evaluated. The reported founder variant in MYBPC3 (c.927-2ANG transition in intron 11) is the main cause (58%) of HCM in Iceland.22MYBPC3 Gln1061X accounts for 17% of HCM cases in Finland26 and is associated with benign or intermediary phenotypes. Another Italian pathogenic founder variant, MYBPC3 p.F305Pfs*27, accounts for about 20% of HCM cases in their cohort.24 Patients carrying this variant also show late onset of HCM and SCD after the fourth decade of life.

The largest study performed to date, which compared CMR phenotypic characteristics among 125 HCM patients carrying MYH7 (53 patients) and MYBPC3 (75 patients) pathogenic variants, found no phenotypic differences between the 2 groups.35 Once again, unfortunately, this study was conducted in patients with already known HCM phenotype and differences in penetrance among patients harboring MYH7 and MYBPC3 pathogenic variants could not be assessed. However, the authors did find differences in patients older than 40 years: MYBPC3 carriers had significantly lower left ventricular ejection fraction.

In Japan, Kubo et al.,28 reported a 76.9% penetrance in their 39 MYBPC3 V592fs/8 carriers, although that study was based on TTE studies only (Table 2). Disease penetrance was 100% in participants older than 50 years and complications such as SCD and left ventricular systolic dysfunction with heart failure also occurred after the age of 50 years. MYBPC3 Val592fs/8 was identified in 16% of HCM probands.28

Table 2.

Comparison Between Founder Pathogenic Variants

Reference  Reported variant  Founder variant carriers  Penetrance evaluated by TTE, %  CMR performed in HCM affected carriers by TTE, %  CMR performed in unaffected carriers by TTE, %  Penetrance evaluated by CMR, % 
Calore et al.24  p.F305Pfs*27  64 (19 probands)  75  25  12.5  Unknown 
Teirlinck et al.25  IVS20-2A>G  34 (9 probands)  61.8  Not reported  Not reported  Unknown 
Sabater-Molina et al.27  p.Pro108Alafs*9  54 (13 probands)  72  20.5  Not reported  Unknown 
Kubo et al.28  V592fs/8  39 (15 probands)  76.9  Not reported  Not reported  Unknown 
Oliva-Sandoval et al.29  IVS23+1G/A  65 (18 probands)  61.5  Not reported  Not reported  Unknown 
This paper update, from Reguero et al.9  G263*  39 (13 probands)  66.7  48.1  91.6  87.2 

CMR, cardiac magnetic resonance; HCM, hypertrophic cardiomyopathy; TTE; transthoracic echocardiography.

Teirlinck et al.25 reported 61.8% HCM penetrance in 34 carriers of MYBPC3 IVS20-2A>G, based on TTE studies without CMR (Table 2). Interestingly, they were diagnosed later in life than carriers with other pathogenic variants in the other genes, despite having experienced the first symptoms at the same age. Presumably, the diagnostic delay was due to delayed appearance of ventricular hypertrophy.25

A study of another Spanish variant, based on TTE in 65 MYBPC3 IVS23+1G/A carriers, reported a penetrance of 61.5% (Table 2).29

Recent studies are beginning to include CMR in their analyses. A penetrance of 72% was reported in the novel Spanish variant MYBPC3 p.Pro108Alafs*9 (Table 2).27 However, in this cohort, CMR was only performed in 8 patients (14.8% of carriers).27

In the 64 carriers of the truncating variant MYBPC3 p.F305Pfs*2, disease penetrance was 75% (Table 2). Nevertheless, CMR was only performed in 12 affected carriers (25% of carriers) and 2 unaffected carriers.24

MYBPC3 p.G263* shares with other truncating pathogenic variants in MYBPC3 the high penetrance with low SCD risk profile and relatively benign clinical course, as previously described in the literature.9 This study provides a clinical update with 5 years’ follow-up, new information on relatives and diagnostic upgrades with CMR. In this pathogenic variant, late onset and life-threatening HCM complications also occurred, but at an advanced age, especially after 40 years, supporting the a priori benign profile of this pathogenic variant. In fact, many patients were asymptomatic at diagnosis (due to familial screening or as an incidental finding). A founder effect has not been proved, nor was it the objective of the study. However, both its high frequency (10% all pathogenic/likely pathogenic variants in HCM) and the historical and geographic isolation of our region, strongly supports the founder effect of the variant.

Not all HCM-related genes with pathogenic variants nor all pathogenic variants in the same gene behave the same way in terms of clinical presentation and outcomes.36 However, in general, pathogenic truncating variants in MYBPC3 seem to behave alike, despite the specific variant. Due to their late onset, their clinical course is, in general, benign. However, clinicians should be aware of possible late life-threatening complications (eg, SCD, stroke, left ventricular systolic impairment, and heart failure), particularly after the age of 40 to 50 years, in contrast to pathogenic variants in other HCM-related genes, whose “in-risk period” would have already been overcome.

Moreover, in our cohort, CMR helped to identify the HCM phenotype. Without CMR, penetrance rates would be similar to those reported in the other MYPBC3 variants (Table 2). In fact, the first time MYBPC3 p.G263* was reported in our population, an apparently low penetrance had been described.9 This reappraisal has allowed updating of its penetrance and clinical expression, identifying HCM patients who would otherwise have gone unnoticed. These data make us wonder whether, in fact, penetrance in other series may also have been underestimated, especially in young patients. As already suggested by Valente et al.,37 a percentage of individuals potentially affected by HCM may go unnoticed without CMR support. In their study, CMR identified mild hypertrophy in about 10% of pathogenic carriers with normal TTE wall thickness. As a result, in family screening of pathogenic variant carriers, when TTE is normal or when images are suboptimal, screening may be upgraded to CMR study.

In addition, in our population, CMR identified 2 patients in whom HMC coexisted with structural features consistent with LVNC. Therefore, this pathogenic variant represents an example of allelic heterogeneity, with variable phenotypic expression in carriers with distinct cardiomyopathies (HCM and LVNC), again raising the question of whether they are actually different manifestations of the same cardiomyopathy spectrum.38 The fact that the 2 patients in our population with LVNC had a stroke and moderate/severe systolic impairment, the 2 most severe complications of this cohort, makes this question intriguing.


Some relatives declined to be clinically or/and genetically studied. Moreover, imaging analysis was not blind, since requests for CMR and TTE specified “HCM familial screening”. As the elapsed time between TTE and CMR tests was not homogeneous and was too long in some patients, caution should be exercised when interpreting these data. Finally, information about age-dependence penetrance is shown in this study. However, many affected patients were asymptomatic and were diagnosed by chance. Therefore, neither the age of first contact with a cardiologist was homogeneous nor could standardized imaging tests be performed (at the same age and with the same periodicity). Thus, assuming further conclusions about age-dependence data in this population was not possible.


The pathogenic variant in MYBPC3 p.G263* shares with most truncating pathogenic variants in this gene 3 characteristics: a late onset; a relatively benign clinical course in the young; and a high age-dependent penetrance. To identify all affected patients, CMR could be a useful tool to evaluate carriers despite an apparently normal TTE.


None declared.


  • The current challenge in HCM, the most common inherited cardiac diseases, lies in the accurate classification of the pathogenicity of variants.

  • The lack of robust data on specific genotype-phenotype associations has reduced its impact on clinical management, beyond screening.


  • We analyzed the pathogenic variant of MYBPC3 p.G263* and reviewed the literature on founder pathogenic variants, seeking possible genotype-phenotype correlations. This variant shares with most truncating pathogenic variants in this gene, the late onset and relatively benign clinical course in the young and a high age-dependent penetrance. Moreover, penetrance could be even higher if evaluated by CMR.

P.M. Elliott, A. Anastasakis, Authors/Task Force members, et al.
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
Eur Heart J., 35 (2014), pp. 2733-2779
S. Sen-Chowdhry, D. Jacoby, J.C. Moon, W.J. McKenna.
Update on hypertrophic cardiomyopathy and a guide to the guidelines.
Nat Rev Cardiol., 13 (2016), pp. 651-675
P. Richard, P. Charron, L. Carrier, et al.
Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy.
Circulation., 107 (2003), pp. 2227-2232
L.R. Lopes, A. Zekavati, P. Syrris, et al.
Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing.
J Med Genet., 50 (2013), pp. 228-239
A.J. Marian, R. Roberts.
The molecular genetic basis for hypertrophic cardiomyopathy.
J Mol Cell Cardiol., 33 (2001), pp. 655-670
S. Richards, N. Aziz, S. Bale, et al.
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Genet Med., 17 (2015), pp. 405-424
A.A. Geisterfer-Lowrance, S. Kass, G. Tanigawa, et al.
A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation.
Cell., 62 (1990), pp. 999-1006
L. Carrier, G. Bonne, E. Bahrend, et al.
Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy.
Circ Res., 80 (1997), pp. 427-434
J.R. Reguero, J. Gómez, M. Martín, et al.
The G263X MYBPC3 mutation is a common and low-penetrant mutation for hypertrophic cardiomyopathy in the region of Asturias (Northern Spain).
Int J Cardiol., 168 (2013), pp. 4555-4556
J. Gómez, J.R. Reguero, C. Morís, et al.
Mutation analysis of the main hypertrophic cardiomyopathy genes using multiplex amplification and semiconductor next-generation sequencing.
Circ J., 78 (2014), pp. 2963-2971
J. Gómez, R. Lorca, J.R. Reguero, et al.
Screening of the Filamin C Gene in a Large Cohort of Hypertrophic Cardiomyopathy Patients.
Circ Cardiovasc Genet., 10 (2017), pp. e001584
C. Riobello, J. Gómez, H. Gil-Peña, et al.
KCNQ1 gene variants in the risk for type 2 diabetes and impaired renal function in the Spanish Renastur cohort.
Mol Cell Endocrinol., 427 (2016), pp. 86-91
E. Coto, B. Tavira, J. Gómez, S. Tranche, C. Díaz Corte.
Effect of the FTO rs9930506 Polymorphism on the Main Comorbidities of the Cardiorenal Metabolic Syndrome in an Elderly Spanish Cohort.
Cardiorenal Med., 4 (2014), pp. 82-87
C. O’Mahony, F. Jichi, M. Pavlou, et al.
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).
Eur Heart J., 35 (2014), pp. 2010-2020
R. Walsh, K.L. Thomson, J.S. Ware, et al.
Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples.
Genet Med., 19 (2017), pp. 192-203
S. Marston, O. Copeland, K. Gehmlich, S. Schlossarek, L. Carrier.
How do MYBPC3 mutations cause hypertrophic cardiomyopathy?.
J Muscle Res Cell Motil., 33 (2012), pp. 75-80
L. Carrier, G. Mearini, K. Stathopoulou, F. Cuello.
Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology.
Gene., 573 (2015), pp. 188-197
H. Niimura, L.L. Bachinski, S. Sangwatanaroj, et al.
Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy.
N Engl J Med., 338 (1998), pp. 1248-1257
S. Sadayappan, P.P. De Tombe.
Cardiac myosin binding protein-C: redefining its structure and function.
Biophys Rev., 4 (2012), pp. 93-106
S. Schlossarek, G. Mearini, L. Carrier.
Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities.
J Mol Cell Cardiol., 50 (2011), pp. 613-620
S.L. Van Driest, V.C. Vasile, S.R. Ommen, et al.
Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
J Am Coll Cardiol., 44 (2004), pp. 1903-1910
B. Adalsteinsdottir, P. Teekakirikul, B.J. Maron, et al.
Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation.
Circulation., 130 (2014), pp. 1158-1167
I. Christiaans, E.A. Nannenberg, D. Dooijes, et al.
Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands.
Neth Heart J., 18 (2010), pp. 248-254
C. Calore, M. De Bortoli, C. Romualdi, et al.
A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.
J Med Genet., 52 (2015), pp. 338-347
C.H. Teirlinck, F. Senni, R.E. Malti, et al.
A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death.
BMC Med Genet., 13 (2012), pp. 105
P. Jaaskelainen, R. Miettinen, P. Karkkainen, L. Toivonen, M. Laakso, J. Kuusisto.
Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes.
Ann Med., 36 (2004), pp. 23-32
M. Sabater-Molina, D. Saura, E. García-Molina Sáez, et al.
A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain.
Rev Esp Cardiol., 70 (2017), pp. 105-114
T. Kubo, H. Kitaoka, M. Okawa, et al.
Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac Myosin-binding protein C gene among Japanese.
J Am Coll Cardiol., 46 (2005), pp. 1737-1743
M.J. Oliva-Sandoval, F. Ruiz-Espejo, L. Monserrat, et al.
Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3.
Heart., 96 (2010), pp. 1980-1984
M.S. Maron, J.J. Finley, J.M. Bos, et al.
Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy.
Circulation., 118 (2008), pp. 1541-1549
J.W. Weinsaft, H.W. Kim, A.L. Crowley, et al.
LV thrombus detection by routine echocardiography: insights into performance characteristics using delayed enhancement CMR.
JACC Cardiovasc Imaging., 4 (2011), pp. 702-712
W.P. Brouwer, T. Germans, M.C. Head, et al.
Multiple myocardial crypts on modified long-axis view are a specific finding in pre-hypertrophic HCM mutation carriers.
Eur Heart J Cardiovasc Imaging., 13 (2012), pp. 292-297
T. Germans, A.A. Wilde, P.A. Dijkmans, et al.
Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations.
J Am Coll Cardiol., 48 (2006), pp. 2518-2523
M.S. Maron, E.J. Rowin, D. Lin, et al.
Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy.
Circ Cardiovasc Imaging., 5 (2012), pp. 441-447
A. Weissler-Snir, W. Hindieh, C. Gruner, et al.
Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (beta-Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy.
Circ Cardiovasc Imaging., (2017),
L.R. Lopes, M.S. Rahman, P.M. Elliott.
A systematic review and meta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations.
Heart., 99 (2013), pp. 1800-1811
A.M. Valente, N.K. Lakdawala, A.J. Powell, et al.
Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy.
Circ Cardiovasc Genet., 6 (2013), pp. 230-237
R. Lorca, M. Martín, J. Gómez, et al.
Hypertrophic cardiomyopathy and left ventricular non-compaction: Different manifestations of the same cardiomyopathy spectrum?.
Int J Cardiol., 190 (2015), pp. 26-28
Copyright © 2018. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.